Records containing: Hypophosphatasia
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-14United States Hypophosphatasia Molecular Research Center
-
CLINICAL_TRIALS study record update · 2026-04-14The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia (HPP) in Children and Adults in Russia
-
CLINICAL_TRIALS study record update · 2026-03-12A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 Years of Age) With Hypophosphatasia (HPP) Previously Treated With Asfotase Alfa
-
CLINICAL_TRIALS study record update · 2026-03-12A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 Years of Age) and Adult Participants With Hypophosphatasia Who Have Not Previously Been Treated With Asfotase Alfa
-
CLINICAL_TRIALS study record update · 2026-03-05Natural History Study of Adult and Pediatric Patients With Hypophosphatasia
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-02-18A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 Years of Age) Participants With Hypophosphatasia Who Have Not Received Previous Treatment With Asfotase Alfa
-
CLINICAL_TRIALS study record update · 2026-02-09A Prospective Observational Sub-Study of the Global Hypophosphatasia Registry to Describe the Potential Risk of Immune-Mediated Loss of Pharmacological Effect of Asfotase Alfa in Participants With Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2025-12-18An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)
-
CLINICAL_TRIALS study record update · 2025-12-16Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2025-05-29Coordination of Rare Diseases at Sanford
-
CLINICAL_TRIALS study record update · 2025-04-04Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns
-
CLINICAL_TRIALS study record update · 2025-02-27Open-Label Pilot Trial to Evaluate the Effects of Ilofotase Alfa on Biomarkers in Adult Patients With Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2025-02-10The COHIR Multi-center Study - a Non-interventional, Prospective, Multi-center Investigation With Exploratory Data Analysis to Assess the Proportion of Patients With Hypophosphatasia Presenting at the Department of Rheumatology and Establishment of an Algorithm to HPP Diagnosis.
-
CLINICAL_TRIALS study record update · 2024-12-27A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2024-07-10A Prospective Study to Evaluate the Patient Reported Quality of Life Prior to and After Strensiq® Treatment in Adults With Pediatric Onset Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2023-12-07The COHIR Study - a Non-interventional, Prospective, Single-center Investigation With Exploratory Data Analysis to Assess the Proportion of Patients With Hypophosphatasia Presenting at the Department of Rheumatology and Establishment of an Algorithm to HPP Diagnosis.
-
CLINICAL_TRIALS study record update · 2023-11-15Characterisation of Adult-Onset Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2023-08-04Single-Center, Case-Control Study of Safety, Efficacy and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) for Treatment of Hypophosphatasia in Children
-
CLINICAL_TRIALS study record update · 2023-01-26Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2022-11-02Clinical Consequences of Adults Presenting With hyPophOsphatasia With Special Focus on Gait, Bone micRosTRucture And cognITion: The PORTRAIT Study
-
CLINICAL_TRIALS study record update · 2022-09-16An Open-label, Intra-patient Dose-escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP).
-
CLINICAL_TRIALS study record update · 2022-07-12An Observational, Longitudinal Study to Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Pediatric-Onset Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2021-12-29Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) Observational Study
-
CLINICAL_TRIALS study record update · 2020-06-04A Phase 4, Randomized, Multicenter, Open-Label, 2-Dosage Regimen, Safety and Tolerability, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia
-
CLINICAL_TRIALS study record update · 2019-03-29An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)